Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-3.68Last Year’s EPS
-3.32Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a strong, high-performing commercial launch (nearly $1B first-year sales), accelerating patient uptake, a sizable and fast-growing U.S. addressable market, a cash-strong balance sheet, and rapid pipeline expansion anchored to Rezdiffra (patent protection to 2045). Key near-term headwinds include expected gross-to-net deterioration into the high 30% range in 2026 (reducing net revenue), Q1 seasonality and contracting timing effects, higher R&D/SG&A from business-development and launch investments, and limited near-term international revenue. Management portrayed confidence in continued robust growth, disciplined R&D/combination strategy, and an adaptive approach to payer partnerships and persistence initiatives.Company Guidance
Exceptional Launch Sales
Fourth quarter 2025 net sales of $321,100,000 (more than triple Q4 2024) and full year 2025 net sales of $958,400,000 — a nearly $1.0B first full year on market, characterized by strong demand and market build-out.
Rapid Patient Growth
Patients on Rezdiffra rose to more than 36,250 at the end of Q4 2025 from more than 29,500 at the end of Q3 2025 — an increase of ~6,750 patients quarter-over-quarter (~22.9% QoQ), indicating steady quarterly net patient adds.
Large and Expanding U.S. NASH Market
Company reports the U.S. F2–F3 target population seen by target specialists expanded nearly 50% since 2023 (discussed range from ~315,000 toward ~460,000 representative patients) and expects the market to grow at a double-digit pace for the foreseeable future.
Pipeline Expansion and Strategic Acquisitions
Company built a pipeline of more than 10 programs via three transactions within ~6 months, adding an oral GLP-1 (phase 1 single-ascending dose study MGL-2086 expected Q2), a late-stage DGAT2 inhibitor (Evogastat), and six preclinical siRNA targets — all intended for combination strategies with Rezdiffra.
Positive Evogastat Phase 2b Evidence
Evogastat (DGAT2 inhibitor) previously completed a phase 2b trial (MIRNA): at the 150 mg dose 72% of patients achieved ≥30% MRI-PDFF reduction and 61% achieved ≥50% reduction — labeled as 'super responder' levels predictive of greater likelihood of fibrosis reversal.
Encouraging F4C Open-Label Data
Two-year open-label NAFLD1 data (122 patients) showed 65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year two, supporting Rezdiffra's potential in F4C and informing the outcomes trial design.
Extended Patent Protection and International Launch Start
Rezdiffra patent exclusivity extended to 2045 and ex-U.S. rollout initiated (Germany), positioning a long commercial runway and the start of international expansion.
Strong Balance Sheet
Cash, cash equivalents, restricted cash, and marketable securities totaled $988,600,000 at year-end 2025, providing resources to support launch, pipeline advancement, and further business development.
MDGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $491.49 | $436.87 | -11.11% |
Nov 04, 2025 | $412.35 | $444.64 | +7.83% |
Aug 05, 2025 | $312.11 | $338.91 | +8.59% |
May 01, 2025 | $333.91 | $327.70 | -1.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Madrigal Pharmaceuticals Inc (MDGL) report earnings?
Madrigal Pharmaceuticals Inc (MDGL) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Madrigal Pharmaceuticals Inc (MDGL) earnings time?
Madrigal Pharmaceuticals Inc (MDGL) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDGL EPS forecast?
MDGL EPS forecast for the fiscal quarter 2026 (Q1) is -3.68.